📊 CTRVP Key Takeaways
Investment Thesis
Hepion Pharmaceuticals is a pre-revenue pharmaceutical company with severe operational losses and negative profitability metrics, burning cash at an unsustainable rate despite holding adequate liquidity. The company lacks revenue generation capability while incurring significant operating expenses, resulting in negative ROE of -310% and operating cash flow burn of -3.3M annually. Without demonstrated clinical progress, revenue generation, or clear path to profitability, the company represents extremely high risk.
CTRVP Strengths
- Strong liquidity position with 10.25x current ratio and $1.8M cash reserves relative to $3.1M total assets
- Minimal debt burden with debt-to-equity ratio of only 0.07x, reducing financial distress risk
- Low absolute liabilities at $402.4K provide operational flexibility
CTRVP Risks
- Complete absence of revenue ($0.00) indicates pre-commercial stage with unproven business model
- Severe cash burn of -$3.3M in operating activities will deplete available cash within 7 months at current burn rate
- Catastrophic profitability metrics including -310% ROE, -269% ROA, and -$8.3M net loss demonstrate inability to generate value
- No insider buying activity in last 90 days suggests lack of confidence from management
- Operating losses of -$4.2M with zero offsetting revenue indicates excessive operating expenses relative to stage
Key Metrics to Watch
- Clinical trial progress and regulatory milestones toward revenue-generating assets
- Monthly operating cash burn rate and runway until capital depletion
- Achievement of first revenue milestone or partnership announcement
CTRVP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 10.25x current ratio provides a solid financial cushion.
CTRVP Profitability Ratios
CTRVP vs Healthcare Sector
How Hepion Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CTRVP Balance Sheet & Liquidity
CTRVP 5-Year Financial Trend
5-Year Trend Summary: Hepion Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-107.35 indicates the company is currently unprofitable.
CTRVP Growth Metrics (YoY)
CTRVP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2024 | N/A | -$2.9M | $-0.56 |
| Q3 2023 | N/A | -$6.9M | $-2.24 |
| Q2 2023 | N/A | -$6.9M | $-3.68 |
| Q1 2023 | N/A | -$6.9M | $-1.82 |
| Q3 2022 | N/A | -$6.1M | $-0.11 |
| Q2 2022 | N/A | -$6.1M | $-0.10 |
| Q1 2022 | N/A | -$6.1M | $-0.09 |
| Q3 2021 | N/A | -$4.2M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CTRVP Capital Allocation
CTRVP SEC Filings
Access official SEC EDGAR filings for Hepion Pharmaceuticals, Inc. (CIK: 0001583771)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CTRVP
What is the AI rating for CTRVP?
Hepion Pharmaceuticals, Inc. (CTRVP) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CTRVP's key strengths?
Strong liquidity position with 10.25x current ratio and $1.8M cash reserves relative to $3.1M total assets. Minimal debt burden with debt-to-equity ratio of only 0.07x, reducing financial distress risk.
What are the risks of investing in CTRVP?
Complete absence of revenue ($0.00) indicates pre-commercial stage with unproven business model. Severe cash burn of -$3.3M in operating activities will deplete available cash within 7 months at current burn rate.
What is CTRVP's revenue and growth?
Hepion Pharmaceuticals, Inc. reported revenue of $0.0.
Does CTRVP pay dividends?
Hepion Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CTRVP SEC filings?
Official SEC filings for Hepion Pharmaceuticals, Inc. (CIK: 0001583771) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CTRVP's EPS?
Hepion Pharmaceuticals, Inc. has a diluted EPS of $-0.88.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.